Are Options Traders Betting on a Big Move in Medpace Stock?
Options traders are showing significant interest in Medpace Holdings (MEDP) stock, specifically the Dec 18, 2026 $370 Put, which has high implied volatility, suggesting expectations of a substantial price movement. Analysts currently rate Medpace Holdings as a Zacks Rank #2 (Buy), with recent upward revisions to earnings estimates. This combination of high implied volatility and positive analyst sentiment could indicate a developing trading opportunity.
T. Rowe Price reports Medpace (MEDP) shares but expressly denies beneficial ownership.
T. Rowe Price Associates, Inc. has filed an amended ownership report for Medpace Holdings, Inc. (MEDP), indicating beneficial ownership of 1,136,251 shares, or 4.1% of the class. Despite reporting sole voting power over 1,105,129 shares and sole dispositive power over all reported shares, T. Rowe Price Associates expressly denied beneficial ownership in the filing. This disclosure provides insight into the investment firm's holdings in Medpace, while also emphasizing their legal stance on the nature of this ownership.
A 5% passive stake in Medpace (MEDP) is reported separately by a manager and its parent.
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have each reported a passive beneficial ownership of 1,396,654 shares in Medpace Holdings, Inc. (MEDP), representing 5.00% of the class as of September 30, 2026. The stakes are reported separately for each entity, with AQR Capital Management, LLC being a wholly owned subsidiary of AQR Capital Management Holdings, LLC. This disclosure was made via a Schedule 13G filing with the SEC.
Medpace Holdings CEO Troendle sells $15.36M in shares
August J. Troendle, CEO of Medpace Holdings (NASDAQ:MEDP), sold 24,741 shares totaling approximately $15.36 million in two September transactions. The sales occurred as the stock neared its 52-week high after a significant 58% gain. Despite the sales, Troendle retains substantial direct and indirect holdings in the company.
Form 4 Medpace Holdings Inc: August J. Troendle (Director, 10% Owner, President & CEO) For: 15 September
This article reports on a Form 4 filing for Medpace Holdings Inc, detailing an insider transaction by August J. Troendle, who serves as a Director, 10% Owner, President, and CEO. The filing pertains to activity on September 15. The brief notice from Investing.com indicates this as a significant disclosure for investors tracking insider movements.
01P.DE Interactive Stock Chart | Medpace Holdings Inc. R Stock
This page provides an interactive stock chart and delayed quote for Medpace Holdings Inc. (01P.DE) on XETRA. The stock closed at EUR 599.40, up 0.64% (+3.80). Users can view various chart ranges and intervals.
Is Medpace Holdings (MEDP) Fully Valued On Record Q3 Awards And Pipeline Growth?
Medpace Holdings (MEDP) is gaining attention due to record Q3 awards and an expanded clinical pipeline, shifting focus to its strong backlog. While some valuations suggest it's overvalued at $536 compared to its $653.11 close, others, like the DCF model, suggest it's slightly undervalued at $696. The article explores these mixed views, noting the company's strong CRO position but also potential risks from biotech funding and trial cancellations.
Earnings Beat Might Change The Case For Investing In Medpace Stock (MEDP)
Medpace Holdings reported better-than-expected Q3 2026 results, with record awards supporting strong earnings and revenue, despite moderated top-line growth. The company is balancing increased demand for clinical development with risks like cancellations and margin variability, which remains a key concern for investors. Analysts project continued earnings growth and revenue increases for Medpace by 2029.
Medpace Holdings Inc (01P.DE) stock price, news, quote and history
This article provides a comprehensive overview of Medpace Holdings Inc (01P.DE) stock performance and financial data. It includes current stock price, historical data, key events, and comparative trailing total returns against the S&P 500. The page also presents valuation measures and financial highlights such as profitability, income statement, balance sheet, and cash flow.
Form 4 Medpace Holdings Inc: Stephen P. Ewald (General Counsel & Corp. Secy.) For: 29 October
This article reports on a Form 4 filing for Medpace Holdings Inc., specifically detailing activity by Stephen P. Ewald, General Counsel & Corp. Secretary, for October 29. Form 4 filings are used to disclose changes in beneficial ownership of securities by a company's officers, directors, and significant shareholders. The article notes Medpace Holdings Inc.'s stock symbol as MEDP.
At $690 a share, Medpace (MEDP) counsel Stephen P. Ewald sells 1,245 shares.
Stephen P. Ewald, General Counsel & Corp. Secy. at Medpace Holdings, Inc. (MEDP), sold 1,245 shares of common stock at $690 per share on October 29, 2026. This transaction reduced his direct holdings to 19,098 shares. The sale was executed via a limit order during an open window period, and no Rule 10b5-1 plan was reported.
Form 4 Medpace Holdings Inc: Stephen P. Ewald (General Counsel & Corp. Secy.) For: 29 October
This article reports on a Form 4 filing by Medpace Holdings Inc, detailing a transaction involving Stephen P. Ewald, the General Counsel & Corp. Secretary, on October 29th. The filing indicates insider trading activity for the company, Medpace Holdings Inc (MEDP).
Medpace Holdings general counsel sells $859,050 in common stock
Stephen P. Ewald, General Counsel and Corporate Secretary at Medpace Holdings (NASDAQ:MEDP), sold 1,245 shares of the company’s common stock for $859,050. The transaction took place on October 29, 2026, at $690 per share, with Ewald retaining 19,098 shares. This sale occurred as the stock neared its 52-week high, with InvestingPro analysis suggesting it might be overvalued.
Form 4 Medpace Holdings Inc: Stephen P. Ewald (General Counsel & Corp. Secy.) For: 29 October
This article reports on a Form 4 filing for Medpace Holdings Inc, detailing a transaction made by Stephen P. Ewald, the General Counsel & Corp. Secretary, on October 29. Form 4 filings are regulatory documents disclosing changes in ownership of company stock by insiders. The article provides this information without further analysis or details of the transaction.
How Medpace Holdings Inc. (MEDP) Affects Rotational Strategy Timing
This article provides an AI-generated analysis of Medpace Holdings Inc. (MEDP) stock, detailing near-term neutral sentiment and potential stalling of mid-term strong sentiment. It outlines three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis for support and resistance levels.
Medpace Holdings, Inc. (MEDP) Seasonal returns chart
The article provides a seasonal returns chart for Medpace Holdings, Inc. (MEDP), displaying the average monthly price return from 2016 to 2026. It includes current stock price information and links to various financial data sections for the company.
Medpace Holdings, Inc. (MEDP) options chain
This article displays the options chain for Medpace Holdings, Inc. (MEDP), showing real-time price data and options contracts. As of the closing date, the stock was trading at $652.01, down 3.77%. The options chain, delayed by 15 minutes, indicated no available calls or puts for the specified date.
Form 144 Medpace Holdings For: 30 October By Investing.com
This article from Investing.com announces the filing of Form 144 for Medpace Holdings (MEDP) on October 30, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief notice provides no further details beyond the company and date.
An officer proposes selling 1,245 Medpace (MEDP) shares through Fidelity Brokerage Services.
Stephen P. Ewald, an officer at Medpace Holdings, Inc. (MEDP), has proposed selling 1,245 common shares with an aggregate market value of $859,050.00. The shares were acquired through a stock option exercise on October 27, 2025, and the approximate sale date is set for October 29, 2026, with Fidelity Brokerage Services LLC acting as broker. The filing highlights the insider transaction and its details, including key figures and relevant financial and regulatory terms.
An EVP sells Medpace (MEDP) shares at $677 each through a limit order.
Susan E. Burwig, Executive Vice President of Medpace Holdings, Inc., sold a total of 20,000 common shares at $677 per share on October 26 and October 27, 2026. These sales were made pursuant to a limit order placed during an open window period. She also exercised options for 328 common shares at $166.73 per share on October 26, 2026, with the option having fully vested on October 27, 2025.
Medpace exec. VP Burwig sells $13.54M in shares By Investing.com
Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings, Inc., sold 20,000 shares of company stock for approximately $13.54 million in late October 2026. These transactions occurred while Medpace stock was trading near its 52-week high, following a strong 67% return over the past six months. Concurrently, Ms. Burwig also exercised employee stock options to acquire 328 shares.
Medpace exec. VP Burwig sells $13.54M in shares
Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings Inc. (NASDAQ:MEDP), sold 20,000 shares of company stock for approximately $13.54 million in late October 2026. These sales occurred while the stock was trading near its 52-week high, though InvestingPro analysis indicates it is overvalued. Concurrently, Burwig also exercised stock options to acquire 328 shares.
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 26 October
This article reports on a Form 4 filing for Medpace Holdings Inc., detailing transactions by Susan E. Burwig, Executive VP of Operations, on October 26. The brief update is a standard financial disclosure, indicating insider activity for the company (MEDP).
An officer proposes selling more Medpace (NASDAQ: MEDP) shares after a $10.9M sale.
Medpace Holdings, Inc. officer Susan Burwig has proposed to sell 3,940 common shares, valued at approximately $2.67 million, with an anticipated sale date of October 27, 2026. This proposed sale follows two previous sales by Burwig in the preceding three months: 7,500 shares on July 28, 2026, for $4.5 million, and 16,060 shares on October 26, 2026, for $10.87 million. The shares being sold were acquired through a stock option exercise on September 26, 2025.
An officer proposes another Medpace (MEDP) share sale after selling $4.5M in July.
Susan E. Burwig, an officer at Medpace Holdings, Inc. (MEDP), has filed a Form 144 proposing to sell 16,060 common shares with an aggregate market value of $10,872,620.00, estimated for October 26, 2026. This proposed sale follows a previous sale of 7,500 shares for $4.5 million on July 28, 2026. The filing also details prior stock option exercises in August and September 2025.
Form 144 Medpace Holdings, Inc. Filed by: BURWIG SUSAN E
Susan E. Burwig, an officer of Medpace Holdings, Inc., has filed a Form 144 notice with the SEC, indicating an intent to sell 16,060 shares of common stock on NASDAQ with an aggregate market value of $10,872,620. The shares were acquired through stock option exercises on August 26, 2025 (10,000 shares) and September 26, 2025 (6,060 shares). The filing also notes previous sales by Susan Burwig of 7,500 shares on July 28, 2026, for gross proceeds of $4,500,000.
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Medpace Holdings, Inc. announced strong financial results for the third quarter of 2026, with revenue increasing 8.5% to $716.0 million and GAAP net income rising to $137.5 million, or $4.84 per diluted share. The company's backlog grew 5.6% to $3,167.2 million, and net new business awards increased by 10.6% to $873.4 million. Medpace also updated its full-year 2026 financial guidance, forecasting revenue between $2.835 billion and $2.855 billion and diluted earnings per share from $17.97 to $18.32, and approved a new $1.0 billion share repurchase authorization through December 31, 2028.
Form 4 Medpace Holdings Inc: August J. Troendle (Director, 10% Owner, President & CEO) For: 25 September
This article reports on a Form 4 filing for Medpace Holdings Inc, detailing insider transactions by August J. Troendle, who serves as a Director, 10% Owner, President, and CEO. The filing pertains to activities on September 25. This type of filing provides transparency into significant ownership changes by company insiders.
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 21 October
This article reports on a Form 4 filing for Medpace Holdings Inc, detailing an insider transaction by Susan E. Burwig, Executive Vice President of Operations, on October 21. The article itself was published on October 24, 2026, at 10:32 AM. It is a brief announcement of the filing without further details on the transaction.
Medpace Holdings, Inc. Estimates – NASDAQ:MEDP
This article provides an overview of Medpace Holdings, Inc. (NASDAQ:MEDP) financial estimates available on TradingView. It highlights where users can explore reported financial data and analyst estimates, including income statement, balance sheet, cash flow, and valuation metrics, for both annual and quarterly periods. The platform allows comparison of actual results with average, high, and low estimates and visualization of trends.
Medpace Holdings Price Target Raised to $700.00/Share From $673.00 by UBS
UBS has raised its price target for Medpace Holdings (NASDAQ: MEDP) to $700.00 per share, up from $673.00. This adjustment follows a positive assessment of the company's financial outlook and market position. The new price target reflects increased confidence in Medpace's future performance.
Medpace Holdings, Inc. Estimates – HAM:01P
This page provides financial data and analyst estimates for Medpace Holdings, Inc. (HAM:01P) on the Hamburg Stock Exchange, including income statement, balance sheet, cash flow, and valuation metrics. Users can explore reported financials, compare them with estimates, and visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Medpace Holdings, Inc. Stock 12‑Month Price Target Raised to $624.33, Implies 6% Downside
The average 12-month price target for Medpace Holdings, Inc. stock has increased from $614.75 to $624.33, based on estimates from 12 analysts. This updated target suggests a potential 6% downside from the Oct. 21 closing price. The consensus rating among 16 analysts remains "Hold," with 2 Buys, 12 Holds, and 2 Sells.
Medpace Holdings stock hits all-time high at 678.0 USD
Medpace Holdings Inc. (MEDP) stock reached an all-time high of $678, with a 1-year return of 21% and a 30% gain over the past six months, boosting its market capitalization to $18.4 billion. Despite its overvalued status according to InvestingPro, the company shows strong investor confidence, aggressive share buybacks, and is trading near its 52-week high. Recent Q2 2026 results exceeded expectations, leading to raised 2026 guidance and positive analyst responses, although some express caution about 2027 revenue.
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Medpace Holdings, Inc. announced strong financial results for the third quarter and first nine months of 2026, with revenue increasing 8.5% year-over-year to $716.0 million and GAAP net income reaching $137.5 million. The company also reported a 16.0% rise in EBITDA to $172.1 million. Medpace has updated its full-year 2026 financial guidance, forecasting revenue between $2.835 billion and $2.855 billion and diluted earnings per share in the range of $17.97 to $18.32, and approved a new $1.0 billion stock repurchase authorization through December 31, 2028.
Medpace Holdings Jumps 5.1% Amid Sector-Wide Rally
Medpace Holdings, Inc. saw its stock surge by 5.1% on Wednesday, October 21, 2026, closing at $654.00, as part of a broader rally in the diagnostics and research sector. The move, which increased its market capitalization to $18.3 billion, occurred alongside significant gains by peers like Charles River Laboratories, Illumina, and Waters Corporation, suggesting a sector-wide capital rotation. Investors are advised to monitor whether this momentum can be sustained and if any fundamental catalysts emerge to explain the coordinated strength.
Medpace schedules October 21 results: what it means for Medpace Holdings stock
Medpace Holdings is set to report its third-quarter 2026 financial results after market close on October 21, 2026, with an earnings call scheduled for October 22. The company will be evaluated on whether its revenue growth surpasses the 17.20% achieved in Q2 2026 and if its operating margin remains near 20.76%. Analysts, including Mizuho, have maintained an "Outperform" rating on the stock prior to the earnings release.
Medpace schedules October 21 results: what it means for Medpace Holdings stock
Medpace Holdings (MEDP) is set to release its third-quarter 2026 results after market close on October 21, 2026, with an earnings call scheduled for October 22, 2026. The company's second-quarter revenue grew 17.20% year over year to $707.33 million, with net income rising 34.50% to $121.36 million. Investors will be watching if revenue growth remains above 17.20% and if the operating margin holds near 20.76%.
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 12 October
This article reports on a Form 4 filing for Medpace Holdings Inc, indicating that Susan E. Burwig, the Executive Vice President of Operations, had a filing for October 12. The specific details of the transaction are not provided within the article's body, which primarily serves as a placeholder for the SEC filing information.
Mizuho lifts target to USD 700 for Medpace stock
Mizuho Securities has increased its price target for Medpace (MEDP) stock from USD 665.00 to USD 700.00, representing an 11.03% increase from its current Nasdaq price. The company is set to report its third-quarter 2026 results on October 21, 2026, and currently trades with a P/E ratio of 36.92 and a market capitalization of USD 17.6 billion.
Medpace Holdings, Inc. (MEDP) Options Chain
This article provides detailed options chain data for Medpace Holdings, Inc. (MEDP), including call and put options. It lists various strike prices, last trade dates, last prices, bid/ask spreads, change, percent change, volume, open interest, and implied volatility for options contracts expiring on October 16, 2026. The data is delayed by 15 minutes and shows the stock trading at $624.68, down 0.62% as of 10:21:47 a.m. EDT on October 16, 2026.
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 12 October
This article reports on a Form 4 filing for Medpace Holdings Inc., indicating an insider transaction by Susan E. Burwig, Executive Vice President of Operations, on October 12. The brief piece primarily serves as an alert for this specific financial disclosure.
Form 4 Medpace Holdings Inc: Susan E. Burwig (Exec. VP, Operations) For: 12 October
This article reports on a Form 4 filing for Medpace Holdings Inc, detailing a transaction by Susan E. Burwig, Executive VP of Operations. The filing pertains to activity on October 12th.
At $166.73 a share, Medpace (MEDP) EVP Susan E. Burwig exercised options for 3,000 shares.
Susan E. Burwig, Executive Vice President of Operations at Medpace Holdings, Inc. (MEDP), exercised options for 3,000 common shares on October 12, 2026, at an exercise price of $166.73 per share. Following this transaction, her holdings increased to 70,984 common shares and 3,028 options. The options had fully vested on October 27, 2025, and the transaction was not conducted under a Rule 10b5-1 plan.
Medpace Holdings: Strong Bookings, But Pass-Through Flatters Growth And The Valuation Leaves Little Room
Medpace Holdings is rated HOLD due to improving bookings and operational trends, but its valuation remains high. While strong backlog and rising awards support the investment case, reported revenue is inflated by pass-through services. The article suggests a neutral portfolio weight until sustained improvements in own-service growth and cash conversion can justify a higher rating, noting that the current price already discounts substantial execution.
Medpace Holdings (MEDP) Following Its Run Higher Looks Pricey Next To Fair Value
Medpace Holdings (MEDP) stock has seen significant gains, with a 152.80% return over three years, closing recently at US$609.89. Despite its strong performance and position as a high-quality CRO focused on small biotechs, the stock appears overvalued at $609.89 compared to a narrative fair value of $536.00. While its P/E ratio of 34.6x is lower than peers and the industry, it's still above an estimated fair ratio of 22.2x, suggesting investors are paying a premium.
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Medpace (MEDP) closed down 1.64% in its latest trading session, underperforming the broader S&P 500 and Dow. The company is set to release its earnings on October 21, 2026, with analysts anticipating a 15.28% rise in EPS and a 7.4% increase in revenue year-over-year. Despite recent gains and a "Hold" rating from Zacks, its Forward P/E and PEG ratios suggest it trades at a premium compared to its industry.
Medpace Investor Ceases Suit Over Clinical Trial Demand Forecast
An investor in Medpace Holdings Inc. has voluntarily dropped a proposed class-action lawsuit accusing the pharmaceutical and medical technology contract research organization of overstating projected demand for its clinical trial services. The investor, Jan Durbin, had alleged Medpace inflated its forecasted book-to-bill ratio for the fourth quarter of 2025. While the claims are ceased, the investor retains the ability to refile the suit.
Form 4 Medpace Holdings Inc: Brian T. Carley (Director) For: 30 September
This article reports on a Form 4 filing for Medpace Holdings Inc, indicating a transaction by Brian T. Carley, a Director, for September 30. The filing is a standard disclosure of insider trading activity.
Form 4 Medpace Holdings Inc: Brian T. Carley (Director) For: 30 September
This article reports on a Form 4 filing for Medpace Holdings Inc (MEDP), indicating that Brian T. Carley, a Director, was involved in a transaction on September 30. The brief notice highlights the insider trading activity without providing further details on the nature or value of the transaction.